Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Acute Sinusitis

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jane Garbutt, MD, Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00377403
First received: September 14, 2006
Last updated: December 24, 2012
Last verified: December 2012

September 14, 2006
December 24, 2012
October 2006
May 2009   (final data collection date for primary outcome measure)
SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 [ Time Frame: 4 days ] [ Designated as safety issue: No ]
The Sino-Nasal Outcomes Test (SNOT-16) assesses disease-specific quality of life for acute and chronic rhinosinusitis. This brief instrument assesses 16 sinus-related symptoms and was administered by phone. The respondent reported how much they were bothered by each item considering both its severity and frequency. Response options include no problem (0), mild or slight problem (1), moderate problem (2), severe problem (3). The SNOT-16 score is the mean score from all 16 items and ranges from 0 (minimal impact) to 3 (significant impact).
Not Provided
Complete list of historical versions of study NCT00377403 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Treatment of Acute Sinusitis
Randomized Clinical Trial to Evaluate Guidelines for Acute Rhinosinusitis (Phase IV Study)

This study will compare the symptom relief provided by 5 cold medicines versus the symptom relief provided by the same 5 cold medicines plus the antibiotic, amoxicillin, in people who have sinus infections. Treatment with amoxicillin may be more effective than treatment with cold medicines alone. Two hundred adult volunteers, aged 18 to 70 years old, with sinus infections will participate in this study for 28 days. Volunteers will receive a 10-day course of either amoxicillin or placebo (substance containing no medication). In addition, all volunteers will receive pain medication, a chest decongestant, nasal decongestants, and cough medicine as needed. Volunteers will be interviewed by telephone on days 0, 3, 7, 10, and 28 following the start of treatment. The study will look at quality of life factors such as change in functional status (ability to perform daily activities) and symptoms, recurrence of the infection, satisfaction with care, and the direct costs of treatment.

The primary objective of this phase IV, randomized, placebo controlled clinical trial is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on disease-related quality of life in adults with clinically diagnosed acute bacterial rhinosinusitis. The secondary objective is to determine the incremental effect of amoxicillin treatment compared with symptomatic treatments on functional status, symptoms, disease recurrence, satisfaction with treatment, and direct costs of treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. The tertiary objective is to identify prognostic indicators for clinical improvement with antibiotic treatment in adults with clinically diagnosed acute bacterial rhinosinusitis. Two hundred adult subjects, 18 to 70 years old, who meet the recommended criteria for acute bacterial rhinosinusitis, will be enrolled from 8 practice sites. Subjects will be randomized to receive a 10-day course of either amoxicillin or placebo. In addition, all subjects will receive an analgesic, an oral decongestant, a nasal saline spray, and an antitussive agent. Subject outcomes will be assessed by telephone interview at 0, 3, 7, 10, and 28 days. The primary outcome is the disease-specific quality of life at Day 3 measured with the SNOT-16, a validated evaluative instrument. Secondary outcomes include change in functional status and symptoms, disease recurrence, satisfaction with care and the direct costs of treatment. Tertiary outcome measures include possible subject and disease-related factors that predict clinical improvement with antibiotic treatment at Day 3 for use in future studies to aid clinical decision-making.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Acute Respiratory Infections
  • Acute Rhinosinusitis
  • Drug: Acetaminophen

    Symptomatic treatment:

    Dose: 500mg every 4 to 6 hours for pain or fever

    Other Name: Tylenol
  • Drug: Amoxicillin

    Intervention drug:

    Dose: 500mg tid for 10 days

    Other Name: Amoxil
  • Drug: Dextromethorphan hydrobromide with guaifenesin

    Symptomatic treatment:

    Dose: 10mls every 4 to 6 hours for cough

    Other Name: Robitussin
  • Drug: Guaifenesin

    Symptomatic treatment:

    Dose: 600mg every 12 hours to thin secretions

    Other Name: Mucinex OTC
  • Drug: Pseudoephedrine Sustained Action

    Symptomatic treatment:

    Dose: 120mg every 12 hours for nasal congestion

    Other Name: Sudafed
  • Drug: Saline spray (0.65%)

    Symptomatic treatment:

    Dose: 2 squeezes per nostril as needed for nasal congestion

    Other Name: Ocean Nasal Spray
  • Experimental: Intervention Arm
    Amoxicillin 500mg three times a day (tid) for 10 days in addition to symptomatic treatments
    Interventions:
    • Drug: Acetaminophen
    • Drug: Amoxicillin
    • Drug: Dextromethorphan hydrobromide with guaifenesin
    • Drug: Guaifenesin
    • Drug: Pseudoephedrine Sustained Action
    • Drug: Saline spray (0.65%)
  • Placebo Comparator: Symptomatic treatments only
    Placebo for 10 days in addition to symptomatic treatments
    Interventions:
    • Drug: Acetaminophen
    • Drug: Dextromethorphan hydrobromide with guaifenesin
    • Drug: Guaifenesin
    • Drug: Pseudoephedrine Sustained Action
    • Drug: Saline spray (0.65%)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
172
August 2010
May 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The subject must be male or female, and between the ages of 18 and 70 years old.
  2. The subject must have symptoms of acute bacterial rhinosinusitis.
  3. The subject must be attending a participating primary care practice in the community.
  4. The subject must have symptoms of acute bacterial rhinosinusitis self-assessed as moderate, severe, or very severe.
  5. The subject must have access to a phone.

Exclusion Criteria:

  1. The subject is less than 18 years old or more than 70 years old.
  2. The subject has very mild or mild symptom severity assessed by self report.
  3. The subject has an allergy to penicillin or amoxicillin.
  4. The subject has received antibiotic therapy within the past 4 weeks (including chronic treatment for acne and low dose prophylactic treatment).
  5. The subject has complications of sinusitis (facial edema, cellulitis, or orbital, meningeal or cerebral signs).
  6. The subject is thought to require intravenous antibiotics or hospital admission.
  7. The subject is pregnant. (This will be assessed by self-report. A pregnancy test will not be required).
  8. The subject has a comorbidity that may impair their immune response (such as immunodeficiency disease, uncontrolled cancer, or chemotherapy or radiation treatment).
  9. The subject has cystic fibrosis.
  10. The subject has Type I diabetes or is taking insulin to treat diabetes.
  11. The subject had prior sinus surgery.
  12. The subject requires an antibiotic for a concurrent condition such as an ear infection.
  13. The subject is not able to complete the study protocol because of language barriers, lack of telephone access, or other issues.
  14. Any other condition that the provider feels may interfere with the study.
Both
18 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00377403
05-0140, U01AI064655-01A1
Yes
Jane Garbutt, MD, Washington University School of Medicine
Washington University School of Medicine
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: Jane Garbutt, MB, ChB Washington University School of Medicine
Washington University School of Medicine
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP